Orthocell Achieves Seventh Consecutive Quarter of Record-Breaking Revenue
Orthocell Limited (ASX: OCC) achieved a record quarterly revenue of AU$3.2 million for the quarter ending 31 December 2025, marking its seventh consecutive quarter of growth. This performance reflects strong sales of its Remplir™ nerve repair product in existing markets and the initial success in the United States. The company has seen a 7% increase from the previous quarter and a 45.2% year-on-year growth. Notably, the U.S. market, supported by a hybrid strategy combining distributors and internal leadership, has shown early success. The company is expanding further with a second Canadian distributor and plans to grow steadily in 2026. Orthocell is financially robust, with AU$49.4 million in cash reserves and anticipates an R&D tax refund of AU$3.0 million in the coming quarter. The company is poised to accelerate product adoption, particularly in the U.S. nerve repair market, projected at US$1.6 billion
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Orthocell Achieves Seventh Consecutive Quarter of Record-Breaking Revenue
Orthocell Limited (ASX: OCC) achieved a record quarterly revenue of AU$3.2 million for the quarter ending 31 December 2025, marking its seventh consecutive quarter of growth. This performance reflects strong sales of its Remplir™ nerve repair product in existing markets and the initial success in the United States. The company has seen a 7% increase from the previous quarter and a 45.2% year-on-year growth. Notably, the U.S. market, supported by a hybrid strategy combining distributors and internal leadership, has shown early success. The company is expanding further with a second Canadian distributor and plans to grow steadily in 2026. Orthocell is financially robust, with AU$49.4 million in cash reserves and anticipates an R&D tax refund of AU$3.0 million in the coming quarter. The company is poised to accelerate product adoption, particularly in the U.S. nerve repair market, projected at US$1.6 billion
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au